Lenalidomide is an immunomodulatory agent that has demonstrated clinical benefit for patients with relapsed or refractory mantle cell lymphoma (MCL); however, despite this observed clinical activity, the mechanism of action (MOA) of lenalidomide has not been characterized in this setting. We investigated the MOA of lenalidomide in clinical samples from patients enrolled in the CC-5013-MCL-002 trial (NCT00875667) comparing singleagent lenalidomide versus investigator's choice single-agent therapy and validated our findings in pre-clinical models of MCL. Our results revealed a significant increase in natural killer (NK) cells relative to total lymphocytes in lenalidomide responders compared to non-responders that was associated with a trend towards prolonged progression-free survival and overall survival. Clinical response to lenalidomide was independent of baseline tumour microenvironment expression of its molecular target, cereblon, as well as genetic mutations reported to impact clinical response to the Bruton tyrosine kinase inhibitor ibrutinib. Preclinical experiments revealed lenalidomide enhanced NK cell-mediated cytotoxicity against MCL cells via increased lytic immunological synapse formation and secretion of granzyme B. In contrast, lenalidomide exhibited minimal direct cytotoxic effects against MCL cells. Taken together, these data provide the first insight into the clinical activity of lenalidomide against MCL, revealing a predominately immune-mediated MOA.
Summary
Lenalidomide is an immunomodulatory agent that has demonstrated clinical benefit for patients with relapsed or refractory mantle cell lymphoma (MCL); however, despite this observed clinical activity, the mechanism of action (MOA) of lenalidomide has not been characterized in this setting. We investigated the MOA of lenalidomide in clinical samples from patients enrolled in the CC-5013-MCL-002 trial (NCT00875667) comparing singleagent lenalidomide versus investigator's choice single-agent therapy and validated our findings in pre-clinical models of MCL. Our results revealed a significant increase in natural killer (NK) cells relative to total lymphocytes in lenalidomide responders compared to non-responders that was associated with a trend towards prolonged progression-free survival and overall survival. Clinical response to lenalidomide was independent of baseline tumour microenvironment expression of its molecular target, cereblon, as well as genetic mutations reported to impact clinical response to the Bruton tyrosine kinase inhibitor ibrutinib. Preclinical experiments revealed lenalidomide enhanced NK cell-mediated cytotoxicity against MCL cells via increased lytic immunological synapse formation and secretion of granzyme B. In contrast, lenalidomide exhibited minimal direct cytotoxic effects against MCL cells. Taken together, these data provide the first insight into the clinical activity of lenalidomide against MCL, revealing a predominately immune-mediated MOA.
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Mantle cell lymphoma (MCL) is a rare and aggressive histological subtype representing approximately 2-7% of nonHodgkin lymphoma (NHL) with a median overall survival (OS) of approximately 4 years (Dreyling et al, 2008) . While the introduction of high dose chemotherapy (with and without autologous stem cell transplantation) and the addition of the anti-CD20 monoclonal antibody, rituximab, to existing regimens has prolonged progression-free survival (PFS) in front line subjects, ultimately the disease remains incurable (Gianni et al, 2003; Romaguera et al, 2005; Delarue et al, 2012) . Despite the availability of agents such as bortezomib, temsirolimus and ibrutinib, the median OS remains poor (less than 2 years) in patients with relapsed or refractory MCL (R/R MCL) Dreyling et al, 2015) . Lenalidomide is an immunomodulatory agent that has demonstrated significant clinical benefit for patients with R/R MCL and is approved for patients who have received at least 2 prior therapies, including the proteasome inhibitor bortezomib (Wiernik et al, 2008; Habermann et al, 2009; Witzig et al, 2011; Goy et al, 2013; Zinzani et al, 2013) . Given the availability of treatment options for R/R MCL and the lack of consensus regarding a standard of care in this setting, the phase 2 MCL-002 (SPRINT) study was designed to evaluate single-agent lenalidomide compared to investigator's choice single-agent therapy, including rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine (Trn en y et al, 2016) . In MCL-002, lenalidomide monotherapy resulted in significant improvements in PFS (8Á7 months) and rates of objective (68%), complete and unconfirmed complete response (5%) compared to investigator's choice [PFS 5Á2 months; overall response rate (ORR) 9%; complete response/unconfirmed complete response (CR/Cru) 0%, respectively], providing the first direct comparison of lenalidomide to other treatment options for R/R MCL (Trn en y et al, 2016).
Lenalidomide and other immunomodulatory drugs (IMiDs) exhibit a dual mechanism of action (MOA), consisting of direct cytotoxic effects against tumour cells as well as targeting the tumour microenvironment through immunomodulation of T and natural killer (NK) cell activity (Schafer et al, 2003; Wu et al, 2008; Yang et al, 2012; Zhang et al, 2013; Gandhi et al, 2014; Offidani et al, 2014) . In NHL, the immunomodulatory effects of lenalidomide include repair of dysfunctional T-cell immune synapses in follicular lymphoma (FL) and chronic lymphocytic leukaemia (CLL) (Ramsay et al, 2008 (Ramsay et al, , 2009 ). Tumour-infiltrating T cells from patients with FL had reduced formation of immune synapses compared to cells from healthy donors; however, treatment with lenalidomide reversed this by enhancing immune synapse formation. Lenalidomide also enhanced rituximab antibody-dependent cellular cytotoxicity (ADCC) in pre-clinical NHL models, which provided pre-clinical support for the investigation of lenalidomide in combination with rituximab combination regimens for patients with NHL (Hernandez-Ilizaliturri et al, 2005; Reddy et al, 2008; Wu et al, 2008; Zhang et al, 2009; Gribben et al, 2015) .
Lenalidomide directly binds Cereblon (CRBN), a substrate receptor for the CRL4 CRBN ubiquitin E3-ligase complex that includes damage-specific DNA binding protein (DDB1), cullin 4A (Cul4) and RING finger protein 1 (ROC1) (Ito et al, 2010) . Upon drug binding to Cereblon, specific substrate proteins are recruited to the E3 ligase and are targeted for ubiquitination and subsequent proteasomal degradation. The first such identified substrates, Ikaros and Aiolos, are lymphoid transcription factors that were found to be degraded to various extents in the presence of thalidomide, lenalidomide and pomalidomide in cell lines from various haematological malignancies including multiple myeloma (MM), myelodysplastic syndrome, diffuse large B-cell lymphoma (DLBCL) and primary T cells (Gandhi et al, 2014; Kronke et al, 2014 Kronke et al, , 2015 Lu et al, 2014; Gribben et al, 2015; Hagner et al, 2015) . In MM cells treated with lenalidomide or pomalidomide, Aiolos and Ikaros degradation resulted in direct cell-autonomous effects including decreased proliferation, which is associated with decreased levels of c-myc (MYC) and interferon regulatory factor 4 (IRF4) (Lu et al, 2014; Bjorklund et al, 2015) . Lenalidomide treatment of T and NK cells resulted in increased interleukin-2 (IL2) and interferon-gamma (IFN-c) secretion, leading to enhanced immune-mediated cytotoxicity including enhanced ADCC (Ramsay et al, 2008; Wu et al, 2008; Gandhi et al, 2014) . Furthermore, Aiolos-deficient NK cells were shown to be strongly hyper-reactive in multiple tumour models (Holmes et al, 2014) . Despite the demonstrated clinical benefits of lenalidomide in R/R MCL and advances into the molecular mechanism in specific lymphoid malignancies, the MOA in MCL has remained largely uncharacterized. Here, we report that patients responding to lenalidomide therapy, but not nonresponders, experienced significant increases in CD56 + NK cells, relative to total lymphocytes, which was associated with a trend towards prolonged PFS and OS. Preclinical experiments revealed that lenalidomide increased NK cell-mediated cytotoxicity against MCL cell lines, primarily through enhanced formation of lytic NK cell immunological synapses and granzyme B secretion; compared to a lack in direct antiproliferative effects against MCL cell lines. These data are consistent with a primarily immune-mediated mechanism of lenalidomide clinical activity in MCL.
Materials and methods

MCL cell culture
Mantle cell lymphoma cell lines (Jeko-1, JVM-2, Mino, Rec1, Granta-519, Z138) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and were cultured in RPMI-1640 medium containing 10-20% fetal bovine serum, 1% penicillin/streptomycin, 2 mmol/l L-glutamine, and 1 mmol/l sodium pyruvate.
Immunoblotting
Cells were lysed in radioimmunoprecipitation assay buffer containing 20 mmol/l Tris, pH 7Á5, 140 mmol/l NaCl, 1 mmol/l EDTA, 1% Nonidet P-40, 10% glycerol, 1 mmol/l sodium orthovanadate, 0Á5 mmol/l dithiothreitol, 1 mmol/l phenylmethylsulfonyl fluoride, 2 lg/ml aprotinin, 2 lg/ml leupeptin and 2 lg/ml pepstatin. Proteins from cell lysates were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (Bio-Rad, Hercules, CA, USA), and transferred to nitrocellulose membranes (Invitrogen, Carlsbad, CA, USA). Immunoblots were probed with antibodies recognizing ITK (2F12) and phospho-BTK (Y223) (Cell Signaling, Danvers, MA, USA). Signals were detected with a Li-Cor Odyssey imager (Li-Cor Biosciences, Lincoln, NE USA).
Isolation of PBMC and NK cells
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coat (New York Blood Center, New York, NY, USA) by Ficoll density gradient centrifugation. NK cells were isolated by negative selection from PBMC according to manufacturer's protocol (Stemcell Tech, Vancouver, BC, Canada). Isolated NK cell purity was over 85% as assessed by flow cytometry using anti-CD3 and anti-CD56 monoclonal antibodies (BD Biosciences, Franklin Lakes, NJ, USA).
PBMC and NK cell co-culture experiments
PBMC and NK cells were treated with dimethyl sulphoxide (DMSO), lenalidomide or ibrutinib for 1 h prior to stimulation with either 3 lg/ml anti-CD3 (OKT3; eBiosciences, Springfield, NJ, USA) for 72 h or 3 ng/ml IL2 (R&D Systems, Minneapolis, MN, USA) overnight, respectively. Prior to co-culturing with MCL cells, target cells were labelled with 200 nmol/l of carboxyfluorescein succinimidyl ester (CFSE; Invitrogen). PBMC or NK cells were co-cultured with target cells at a defined ratio for an additional 4 h. Subsequently, supernatant was collected for Granzyme B enzyme-linked immunosorbent assay (ELISA) and apoptosis in labelled target cells was determined by flow cytometric analysis of Annexin V (BD Biosciences) and ToPro-3 (Invitrogen) according to manufacturer's protocol. See supplemental experimental procedures for additional details.
Results
NK cells increase relative to total lymphocytes in patients with MCL who respond to lenalidomide therapy
Lenalidomide has demonstrated clinically significant benefits in patients with R/R MCL; however, the molecular mechanism in MCL has not been described. In vitro studies have demonstrated lenalidomide has a dual MOA in other haematological malignancies that includes both immunomodulatory effects on multiple immune cell types as well as cell autonomous apoptotic activity (Mitsiades, 2002; Schafer et al, 2003; Wu et al, 2008; Lopez-Girona et al, 2011; Gandhi et al, 2014) . In a post-hoc analysis of biomarker data collected in the CC-5013-MCL-002 trial, we sought to examine the immunomodulatory effects of lenalidomide using samples collected from patients who had been treated with either lenalidomide or investigator's choice (single agent rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine) (Trn en y et al, 2016). Peripheral blood samples were collected at Cycle 1 Day 1 (C1D1, pre-treatment), Cycle 1 Day 4 (C1D4) and Cycle 2 Day 15 (C2D15). Flow cytometric profiling of T cell (CD3/CD4/CD8/CD45RA/CD25/CD27), B-cell (CD19/CD20/CD5/CD23/CD40/CD22/Kappa/Lambda) and NK cell (CD56/CD16/CD3/CD69) subsets was performed. In baseline measurements of B-, T-and NK cells (total or subset populations), no significant differences were observed when comparing non-responder (stable or progressive disease) and responder (complete or partial response) outcome sub-groups in either lenalidomide (N = 50) or investigator's choice control (N = 18) arms (data not shown). However, we detected significantly elevated (P ≤ 0Á05) levels of NK cells, as measured by CD3 À CD56 + CD16 + , relative to total lymphocytes in patients who responded to lenalidomide (N = 20) at both C1D4 and C2D15. Most importantly, this increase at C1D4 was also significantly different between responders compared to non-responders (N = 14) in the lenalidomide arm ( Fig 1A) . These observations were independent of baseline demographics, such as age (71 years 9Á8% observed at C1D4 demonstrated a trend towards prolonged PFS (median of 48Á7 weeks vs. 16Á9 weeks, P = 0Á11) (Fig 1B) . Additionally, there was a trend towards enhanced OS (median of undefined versus 86Á7 weeks, P = 0Á08) ( Fig 1C) . Taken together, these data provide a potential pharmacodynamic marker for response to lenalidomide in patients with R/R MCL and suggest that a lenalidomidedependent increase in NK cells may partly contribute to extended PFS and OS.
Clinical response to lenalidomide is not associated with baseline tumour microenvironment cereblon expression or with mutations reported to impact response to ibrutinib
We investigated the association of cereblon protein levels with clinical response by analysing lymph node biopsies from R/R MCL patients enrolled in MCL-002. As shown in representative images in Fig 2A, cereblon was expressed at similar levels in patients with differing responses to therapy and quantitative H-scores for cereblon protein levels in total, nuclear, and cytoplasmic compartments did not correlate with clinical response to lenalidomide (Fig 2B) . Previous studies have demonstrated that mutations in epigenetic regulators, MTOR signalling and the Bruton tyrosine kinase (BTK) pathway, specifically CREBBP, CD79A, ERBB4, KMT2D, MTOR, PLCG2 and NSD2 genes, negatively correlate with clinical response to ibrutinib in MCL (Balasubramanian et al, 2014; Lenz et al, 2016) . To determine if mutations in these seven genes influenced response to lenalidomide, we sequenced 19 patients (7 responders and 12 non-responders) from the MCL-002 trial using the Foundation One Heme panel (Foundation Medicine, Cambridge, MA, USA). Our analysis suggested that lenalidomide retains activity in MCL patients whose tumours contain mutations that are associated with ibrutinib resistance, specifically KMT2D where 7 patients achieved clinical outcomes of 4 responders and 3 non-responders (Fig 2C) .
Lenalidomide increases immune cell-mediated cytotoxicity against MCL cell lines while ibrutinib does not
To further investigate the immunomodulatory effects of lenalidomide we utilized an in vitro co-culture cytotoxicity assay. CD3-stimulated PBMCs were treated with DMSO or lenalidomide (1 nmol/l to 10 lmol/l) for 3 days prior to co-culture with CFSE-labelled MCL cell lines. Increasing the concentration of lenalidomide resulted in a 3-to 6Á9-fold increase in CD3-stimulated immune cell-mediated cell death in Jeko-1, Granta-519, and Mino MCL cell lines as measured by Annexin V and ToPro-3 staining. Treatment with 10 lmol/l lenalidomide was significantly more effective at inducing PBMC-mediated apoptosis in all three MCL cell lines as compared to DMSO controls (P ≤ 0Á05 Jeko-1, P ≤ 0Á0001 Granta-519, P ≤ 0Á001 Mino) (Fig 3A, left panel) . In contrast, treatment with ibrutinib (10 nmol/l to 1 lmol/l) for 3 days prior to a 4-h co-culture with the same three MCL cell lines revealed no significant difference in induction of apoptosis compared to DMSO-treated PBMCs (Fig 3A,  right panel) . In addition, analysis of the supernatant from these co-culture assays revealed that lenalidomide treatment increased secreted granzyme B levels in a dose-dependent manner compared to vehicle controls (Fig 3B, left panel) ; however, treatment with ibrutinib did not result in increased granzyme B secretion (Fig 3B, right panel) . Together, the functional cytotoxicity assays buttress the ability of lenalidomide to potentiate the immune-mediated killing of MCL tumour cells and reveal granzyme B as a potentially important immunological marker.
Given the duality of lenalidomide's MOA in other disease settings, such as MM and DLBCL, we next examined the cell autonomous effects of lenalidomide in MCL. We first examined whether treatment with lenalidomide (0Á01 nmol/l to 10 lmol/l) impacted tumour cell proliferation by screening a panel of six MCL cell lines (Granta-519, Jeko-1, Mino, JVM-2, Rec-1, and Z138) for 5 days. Surprisingly, treatment with lenalidomide did not result in any significant changes in cellular proliferation as measured by 3 H-thymidine incorporation (Fig S1A) or apoptosis in any of the MCL cell lines tested (Fig S1B) . In contrast to lenalidomide, MCL cells treated with ibrutinib (0Á01 nmol/l to 10 lmol/l) or doxorubicin (150 nmol/l to 10 lmol/l) for 5 days resulted in decreased proliferation (Fig S1C,D) .
Lenalidomide enhances NK cell-mediated cytotoxicity and lytic immune synapse formation
To determine whether NK cells were responsible for the ability of lenalidomide to promote immune-mediated cytotoxicity against MCL tumour cells, we utilized our in vitro co-culture cytotoxicity assay using negatively isolated CD56 + NK cells. IL2-stimulated NK cells treated with 1 nmol/l to 10 lmol/l lenalidomide for 18 h prior to the co-culture with MCL cells resulted in remarkably similar anti-tumour activity to that observed in the previous co-culture assay using PBMCs (Fig 4A) . Lenalidomide-treated NK cells were significantly more effective at inducing NK cell-mediated apoptosis of all three MCL cell lines when compared to vehicle treated cells (P ≤ 0Á01 Jeko-1, P ≤ 0Á01 Granta-519, P ≤ 0Á01 Mino) (Fig 4A) . In contrast, treatment with 0Á5 lmol/l ibrutinib resulted in significantly reduced levels of apoptosis as measured by Annexin V/ToPro-3 staining in all 3 MCL cell lines (P ≤ 0Á0001 Jeko-1, P ≤ 0Á01 Granta-519, P ≤ 0Á0001 Mino) compared to vehicle-treated NK cells (data not shown). Moreover, supernatants from lenalidomide-treated co-cultures of NK cells with MCL cells revealed significantly increased granzyme B levels when compared to vehicle controls (P ≤ 0Á0001 Jeko-1, P ≤ 0Á01 Granta-519) (Fig 4B) . Supernatants from ibrutinib-treated NK cells revealed significantly decreased levels of granzyme B compared to vehicle control treatment (P ≤ 0Á0001 Jeko-1 and Granta-519), suggesting that ibrutinib inhibits NK cell-mediated cytotoxicity (Fig 4B) . The tyrosine kinase IL2 inducible T cell kinase (ITK), has been shown to positively regulate FccRIII (also known as CD16) mediated NK cell cytotoxicity and ADCC (Khurana et al, 2007) . Given the homology between BTK and ITK, we explored ibrutinib treatment on ITK activation in CD16 cross-linked NK cells. Ibrutinib resulted in decreased phosphorylation at tyrosine 180 (Y180) of ITK, confirming ITK as a known target of ibrutinib (Fig 4C) (Dubovsky et al, 2013) . These data are consistent with previous reports indicating that ibrutinib antagonized rituximab- Total, nuclear and cytoplasmic cereblon (CRBN) were scored using an H-score system. Box and whisker plots for H-scores grouped by best overall response to lenalidomide. Progressive disease, n = 7; stable disease, n = 17; partial response, n = 21. (C) Graphical representation of mutational status for CREBBP, CD79A, ERBB4, KMT2D, MTOR, PLCG2 and NSD2 compared to best overall response from biopsies (n = 19) obtained prior to lenalidomide treatment.
dependent NK cell-mediated cytotoxicity Rajasekaran et al, 2014; Roit et al, 2014) , however one group has demonstrated that ibrutinib increased NK cell-mediated activity of mouse NK cells (Kuo et al, 2016) . The addition of anti-CD20 monoclonal antibodies, such as rituximab and obinutuzumab (GA101), to standard therapies has significantly improved responses in multiple haematological malignancies (Coiffier et al, 2002; Goede et al, 2014) . Lenalidomide has been shown to enhance ADCC and has demonstrated significant clinical benefit in NHL (HernandezIlizaliturri et al, 2005; Wu et al, 2008; Zhang et al, 2009; Wang et al, 2012; Fowler et al, 2014; Nowakowski et al, 2014; Ruan et al, 2015) . We sought to investigate the effect of lenalidomide in combination with CD20 targeting antibodies in a PBMC co-culture model. Expression of CD20 was confirmed via flow cytometry in Z138, JVM-2, and Granta-519 cell lines (Fig S2A) . CD3-stimulated PBMCs were treated with lenalidomide (0Á1 or 1 lmol/l) for 3 days prior to a 4-h co-culture with Granta-519, JVM-2 or Z138 cells that had been labelled with rituximab or obinutuzumab. Treatment with lenalidomide enhanced rituximab and obinutuzumab ADCC against all three MCL cell lines (Figs 4D,  S2B) . Interestingly, the combination of lenalidomide with obinutuzumab was more potent than the combination with rituximab in all three cell lines, resulting in approximately 30% of MCL cells remaining viable following only 4 h of co-culture.
Conditional deletion of Aiolos from NK cell lineages has been previously reported to result in NK cells that were hyper-reactive against tumour cells (Holmes et al, 2014) . We examined the effect of lenalidomide treatment on Aiolos and Ikaros protein expression in CD56 + NK and CD3 + T cells following treatment of PBMC with increasing concentrations of lenalidomide (1 nmol/l to 10 lmol/l) for 3 days compared to vehicle control. Our results showed that lenalidomide treatment decreased Aiolos and Ikaros levels in CD3 + T cells, which is consistent with previous reports (Fig 4F) (Gandhi et al, 2014; Kronke et al, 2014) . We also observed degradation of both Aiolos (40%) and Ikaros (95%) after lenalidomide treatment in CD56 + NK cells (Fig S3A) , suggesting that degradation of Aiolos and Ikaros may increase persistent NK cell activity against tumour cells. We hypothesized that lenalidomide treatment could modulate the immunological synapse, which is the dynamic signalling interface formed between a NK cell and a target cell. Formation of the NK cell immune synapse controls the directed delivery of lytic granule contents for targeted cell lysis. F-actin polymerization is a hallmark of the activated NK cell lytic synapse, whereas the inhibitory immune synapse observed in NK cells is primarily actin-independent (Orange, 2008) . Using confocal microscopy, we investigated the effects of lenalidomide on F-actin polymerization by visualizing NK: MCL cell conjugate interactions. Treatment of Jeko-1 and CD56 + NK cells for 24 h with 1 lmol/l lenalidomide prior to 30 min of co-culture resulted in increased F-actin polymerization as compared to DMSO control (Fig 4E) . This increase in F-actin polymerization and focal expression pattern are characteristic of an immune synapse ( Dustin, 2004). Quantification of immune synapse formation in three independent experiments revealed that treatment with lenalidomide resulted in a statistically significant increase in immune synapse strength as measured by F-actin polymerization at the contact between a NK cell and a Jeko-1 cell (P ≤ 0Á0001). Additionally, significant relocalization of perforin to the immune synapse (P ≤ 0Á0001), a primary attribute of a functional lytic synapse, was observed (Fig 4F) .
Discussion
Lenalidomide has significant activity in B-cell malignancies such as MM and NHL, including DLBCL, FL and MCL (Wiernik et al, 2008; Benboubker et al, 2014; Leonard et al, 2015; Trn en y et al, 2016) . To date, the mechanistic understanding of lenalidomide's anti-tumour activity was understood to be a combination of both direct cell autonomous and immune-mediated effects. In this study, we provide novel evidence that the clinical activity of lenalidomide in MCL is mediated through activation of NK cell-directed cytotoxicity in patients. A subset analysis of longitudinal collected biomarker samples reveals that MCL patients enrolled on the MCL-002 trial who responded to lenalidomide had a significant expansion of CD56 + CD16 + NK cells relative to total lymphocytes compared to non-responders. Notably, this NK cell expansion was measurable as early as 4 days posttreatment initiation. Our correlative studies reveal that those patients whose NK cells expanded above the median increase for this population had a trend towards prolonged PFS and improved OS compared to patients whose NK cells expansion was below the median increase threshold. Interestingly, profiling of T cell subsets revealed a significant increase in CD4 + CD25 + activated T cells in lenalidomide-treated patients at C2D15 compared to C1D1 (data not shown). However, this effect was not significantly different between responders and non-responders to lenalidomide. Further supporting the concept of an immune mediated anti-tumour process, lenalidomide exhibits activity in patients with a spectrum of lymphoma-associated mutations including those that have been correlated with disruption of ibrutinib activity in both MCL and CLL (Balasubramanian et al, 2014; Woyach et al, 2014) , however these observations should be confirmed in a larger cohort. While the precise molecular mechanism of lenalidomide's enhancement of NK cell activity is unknown, we describe a shared mechanism with T cells in that engagement of lenalidomide with CRL4
CRBN results in decreased levels of the transcription factors Aiolos and Ikaros through ubiquitination and subsequent proteasomal degradation. Genetic deletion of Aiolos has been reported to significantly enhance NK-mediated anti-tumour effects (Holmes et al, 2014) . Interestingly, lenalidomide treatment of NK cells has been shown to result in enhanced IFN-csecretion and actin remodelling as early as 90 min post-treatment, when degradation of Aiolos and Ikaros by CRL4 CRBN is minimal (Lagrue et al, 2015) . We hypothesize that the polymerization of F-actin and relocalization of perforin, two characteristics of an active immunological synapse, that were observed in our studies may be a distinct and independent mechanism from degradation of Aiolos and Ikaros and is currently under further investigation.
In conclusion, we believe these data identify a distinct immune-mediated MOA for lenalidomide in MCL that should be confirmed in larger clinical studies. Lenalidomide treatment enhanced NK cell-mediated cytotoxicity by promoting lytic immune synapse formation and polarized granzyme B release. Furthermore, the improvement of anti-CD20 mediated ADCC following lenalidomide treatment provides pre-clinical mechanistic support for the combination of lenalidomide with anti-CD20 antibodies in MCL, which has shown remarkable clinical activity in this disease setting with an ORR of 92%, CR rate of 64% and 2-year PFS of 85% (Ruan et al, 2015) . 
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